Back to Search
Start Over
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease
- Source :
- European Heart Journal, 42(23), 2265-2269. Oxford University Press, Ten Berg, J, Sibbing, D, Rocca, B, Van Belle, E, Chevalier, B, Collet, J-P, Dudek, D, Gilard, M, Gorog, D A, Grapsa, J, Grove, E L, Lancellotti, P, Petronio, A S, Rubboli, A, Torracca, L, Vilahur, G, Witkowski, A & Mehilli, J 2021, ' Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation : a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease ', European Heart Journal, vol. 42, no. 23, pp. 2265-2269 . https://doi.org/10.1093/eurheartj/ehab196, European Heart Journal, European Heart Journal, 2021, 42 (23), pp.2265-2269. ⟨10.1093/eurheartj/ehab196⟩
- Publication Year :
- 2021
-
Abstract
- Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.
- Subjects :
- medicine.medical_specialty
Percutaneous
Consensus
Settore BIO/14 - FARMACOLOGIA
[SDV]Life Sciences [q-bio]
Heart Valve Diseases
030204 cardiovascular system & hematology
Lower risk
law.invention
Transcatheter Aortic Valve Replacement
03 medical and health sciences
0302 clinical medicine
Antithrombotic treatment
Transcatheter aortic valve implantation
Aged
Aortic Valve
Fibrinolytic Agents
Humans
Treatment Outcome
Aortic Valve Stenosis
Heart Valve Prosthesis Implantation
Thrombosis
Randomized controlled trial
law
Internal medicine
Antithrombotic
medicine
030212 general & internal medicine
Adverse effect
Aortic Valve/surgery
ANTIPLATELET THERAPY
business.industry
Fibrinolytic Agents/therapeutic use
valvular heart disease
Thrombosis/drug therapy
medicine.disease
Stenosis
Aortic Valve Stenosis/drug therapy
Transcatheter Aortic Valve Replacement/adverse effects
Cardiology
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- Language :
- English
- ISSN :
- 0195668X and 15229645
- Database :
- OpenAIRE
- Journal :
- European Heart Journal, 42(23), 2265-2269. Oxford University Press, Ten Berg, J, Sibbing, D, Rocca, B, Van Belle, E, Chevalier, B, Collet, J-P, Dudek, D, Gilard, M, Gorog, D A, Grapsa, J, Grove, E L, Lancellotti, P, Petronio, A S, Rubboli, A, Torracca, L, Vilahur, G, Witkowski, A & Mehilli, J 2021, ' Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation : a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease ', European Heart Journal, vol. 42, no. 23, pp. 2265-2269 . https://doi.org/10.1093/eurheartj/ehab196, European Heart Journal, European Heart Journal, 2021, 42 (23), pp.2265-2269. ⟨10.1093/eurheartj/ehab196⟩
- Accession number :
- edsair.doi.dedup.....75b70e60ddc5c34112f642855da485d1